Heparin, Low-Molecular-Weight

"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.

Descriptor ID	D006495
MeSH Number(s)	D09.698.373.400.300
Concept/Terms	Heparin, Low-Molecular-Weight Heparin, Low-Molecular-Weight Heparin, Low Molecular Weight LMWH Low Molecular Weight Heparin Low-Molecular-Weight Heparin

Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".

Chemicals and Drugs [D]
Carbohydrates [D09]
Polysaccharides [D09.698]
Glycosaminoglycans [D09.698.373]
Heparin [D09.698.373.400]
Heparin, Low-Molecular-Weight [D09.698.373.400.300]

Below are MeSH descriptors whose meaning is related to "Heparin, Low-Molecular-Weight".

Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".

Heparin, Low-Molecular-Weight
Dalteparin
Enoxaparin
Nadroparin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.

Bar chart showing 53 publications over 24 distinct years, with a maximum of 6 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	1	0	1
1998	1	0	1
1999	1	0	1
2000	0	1	1
2001	0	1	1
2002	1	2	3
2003	1	0	1
2004	1	1	2
2005	1	5	6
2006	1	0	1
2007	3	2	5
2008	2	1	3
2009	1	1	2
2010	1	1	2
2011	0	3	3
2012	1	0	1
2015	2	2	4
2016	2	1	3
2019	0	1	1
2020	1	0	1
2021	1	1	2
2022	2	1	3
2023	1	3	4

Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.

Mou D, Falconer E, Majumdar M, Delgado T, Fay K, Hall CE, Smach C, Ashraf S, Levett S, Lin E, Davis S, Patel A, Stetler J, Serrot F, Srinivasan J, Oyefule O, Diller M, Hechenbleikner E. Achieving durable compliance with venous thromboembolism prophylaxis in bariatric surgery: 3-year data from a major academic medical center. Surg Obes Relat Dis. 2024 01; 20(1):72-79.

View in: PubMed
Al Tannir AH, Biesboer EA, Pokrzywa CJ, Figueroa J, Harding E, de Moya MA, Morris RS, Murphy PB. The efficacy of various Enoxaparin dosing regimens in general surgery patients: A systematic review. Surgery. 2023 08; 174(2):315-323.

View in: PubMed
Pokrzywa CJ, Biesboer EA, Figueroa J, Al Tannir AH, de Moya M, Morris RS, Murphy PB. Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients. J Am Coll Surg. 2023 08 01; 237(2):195-203.

View in: PubMed
Parvizi J, DeMik DE, Hozack WJ, Dunbar MJ, Mont MA, Lachiewicz PA. Commentary on "Low Molecular Weight Heparin is Superior to Aspirin in the Prevention of Thromboembolic Disease, or is It? Response to an Editorial". J Arthroplasty. 2023 04; 38(4):e9.

View in: PubMed
Agasthya N, Froehlich CD, Golecki M, Meyer M, Ogino MT, Froehlich K, Beaty C, McCants S, Maul TM, Dirnberger DR. Single-Center Experience Using the Cardiohelp System for Neonatal and Pediatric Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med. 2023 04 01; 24(4):e190-e195.

View in: PubMed
Parvizi J, DeMik DE, Hozack WJ, Dunbar MJ, Mont MA, Lachiewicz PF. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It? J Arthroplasty. 2023 Jan; 38(1):1-2.

View in: PubMed
Parvizi J, DeMik DE, Dunbar M, Hozack WJ, Mont MA, Lachiewicz PF. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It? J Bone Joint Surg Am. 2022 12 07; 104(23):2045-2046.

View in: PubMed
Merli GJ, Kraft WK, Eraso LH, Galanis T, Thomson LJ, Ouma GO, Viscusi E, Gong JZ, Lam E. Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study. Vasc Med. 2022 06; 27(3):269-276.

View in: PubMed
Myers DD, Ning J, Lester P, Adili R, Hawley A, Durham L, Dunivant V, Reynolds G, Crego K, Sood S, Sigler R, Fogler WE, Magnani JL, Holinstat M, Wakefield T. E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2022 01; 10(1):211-220.

View in: PubMed
Graif A, Kimbiris G, Grilli CJ, Agriantonis DJ, Putnam SG, Leung DA. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol. 2020 Apr; 31(4):537-543.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement